SCHEMBL6579440

SCHEMBL6579440

CCCCCc1cccnc1-c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
HTT P42858 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MYC P01106 1/20 0.40
GCGR P47871 8/20 0.39
MAPK14 Q16539 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
ALOX5 P09917 1/20 0.38
PTGS2 P35354 1/20 0.38
GPR84 Q9NQS5 1/20 0.37
TRPV1 Q8NER1 2/20 0.37
TLR8 Q9NR97 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28090328 0.86 GPR84 (0.50) NPC1HTTRAB9ASMN1; SMN2LMNA
SCHEMBL2955779 0.84 GPR84 (0.49) NPC1HTTRAB9ASMN1; SMN2LMNA
SCHEMBL28062636 0.84 GPR84 (0.49) NPC1HTTRAB9ASMN1; SMN2LMNA
SCHEMBL3833757 0.82 LIPG (0.50) HTTTP53MAPTTDP1L3MBTL1
SCHEMBL8720799 0.82 LIPG (0.50) HTTTP53MAPTTDP1L3MBTL1
SCHEMBL18778553 0.81 GPR84 (0.44) NPC1HTTRAB9ASMN1; SMN2LMNA
SCHEMBL3907145 0.80 MAOB (0.44) MYCMAPK14TRPV1
SCHEMBL9806810 0.78 S1PR1 (0.43) NPC1HTTRAB9ASMN1; SMN2LMNA
SCHEMBL9806788 0.78 MYC (0.38) NPC1HTTRAB9ASMN1; SMN2GAA
SCHEMBL10665776 0.78 S1PR1 (0.43) NPC1HTTRAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140083-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-02 EP disclosed
US-6469018-B1 INHIBITING CYTOKINES AND THE TREATMENT OF A CYTOKINE MEDIATED DISEASE, BY ADMINISTRATION OF COMPOUNDS SUCH AS:2-(4-FLUOROPHENYL)-3-(2-METHYLTHIOPYRIMIDIN-4-YL)PYRIDINE SMITHKLINE BEECHAM CORPORATION 2002-10-22 US disclosed
EP-1140083-A1 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2001-10-10 EP disclosed
WO-2000040243-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-13 WO disclosed